Isolation of rare circulating tumor cells in cancer patients: technical aspects and clinical implications (Articolo in rivista)

Type
Label
  • Isolation of rare circulating tumor cells in cancer patients: technical aspects and clinical implications (Articolo in rivista) (literal)
Anno
  • 2011-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1586/ERM.11.33 (literal)
Alternative label
  • Danova M, Torchio M, Mazzini G (2011)
    Isolation of rare circulating tumor cells in cancer patients: technical aspects and clinical implications
    in Expert review of molecular diagnostics; Expert Reviews, London (Regno Unito)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Danova M, Torchio M, Mazzini G (literal)
Pagina inizio
  • 473 (literal)
Pagina fine
  • -485 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 11 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 13 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 5 (literal)
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1. Osped Civile Vigevano, I-27029 Pavia, Italy 2. Univ Pavia, Ist Genet Mol IGM, CNR, I-27100 Pavia, Italy 3. Univ Pavia, Dipartimento Biol Anim, I-27100 Pavia, Italy (literal)
Titolo
  • Isolation of rare circulating tumor cells in cancer patients: technical aspects and clinical implications (literal)
Abstract
  • Abstract: Circulating tumor cells (CTCs) may be detected in the blood of patients with epithelial tumors using different analytical approaches. The relative number of CTCs is low and they include a heterogeneous population of cells with diverse biological and molecular characteristics, often different from those of the respective primary tumor. Until recently, they have been difficult to detect and, even though discordant results have been reported when different methods of detection were used, they may provide prognostic and predictive information. Several antibody- or molecular-based CTC detection methods have been developed, offering hope for individualized risk assessment by utilizing CTCs as biomarkers of disease progression and drug response. Pilot studies have also shown that by utilizing methods that permit, besides enumeration, a molecular characterization of CTCs, one could better identify high-risk patients, predict response to targeted therapies, analyze gene expression profiles (in order to identify new potential drug targets) and increase our knowledge of the metastatic process. In this article we review the techniques currently utilized for isolation and characterization of CTCs and we discuss their potential utility in clinical oncology focusing on the future perspectives in this field (literal)
Editore
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Editore di
Insieme di parole chiave di
data.CNR.it